LONDON, Dec. 3, 2019 /PRNewswire/ -- Smith+Nephew
(LSE:SN, NYSE:SNN), the global medical technology business, is
pleased to announce the completion of the first surgeries utilizing
its new JOURNEY II Unicompartmental Knee (UK) System. Built on the
heritage of the most clinically successful partial
knee,1,2 JOURNEY II UK is designed to help patients
rediscover their normal life before they first experienced knee
pain.
The new JOURNEY II UK system is designed to provide faster
recovery,3-6 improved functionality4,7-10 and
higher patient satisfaction9,11-14 than other
unicompartmental options. It does this by incorporating both an
increased size range and lateral specific implant, which enables
surgeons performing partial knee arthroplasty to maintain the
shape, position and motion15 of a normal knee joint –
critical to improving patient outcomes.
"The new JOURNEY II Unicompartmental Knee System combines a
straightforward surgical technique with an implant offering
additional sizes for optimal coverage," said Dr. Kevin Fricka, Orthopaedic Surgeon, Anderson
Orthopaedic Clinic. "I am very excited for what this new system can
do for my patients by enabling faster recovery and improved
functionality, and I am very encouraged by the outcomes from my
first cases."
JOURNEY II UK is also meant to drive value and
cost-effectiveness through a reduced OR footprint.16-18
Studies show that unicompartmental procedures may result in
thousands of dollars in cost savings to payers via decreased
implant and procedure costs.16 And, when used in
conjunction with its NAVIO™ Handheld Robotics and VISIONAIRE™
Patient Matched Instrumentation, Smith+Nephew offers
healthcare providers a comprehensive solution to partial knee
replacements that no other company can match.
"We are thrilled to introduce the JOURNEY II Unicompartmental
Knee System - a combination of the most successful and innovative
design features of our knee arthroplasty portfolio," said
Skip Kiil, President of Orthopaedics
at Smith+Nephew. "Combining cost-effective solutions for healthcare
systems with the potential for better patient outcomes is a
win-win, and underscores our purpose of helping people restore
their bodies and their self-belief."
Smith+Nephew has a rich history with unicompartmental knees –
including one of the first-ever commercially produced
systems.19 JOURNEY II UK continues this evolution
utilizing best-in-class technology from Smith+Nephew's highly
successful JOURNEY II platform as well as its ZUK Unicompartmental
Knee – the most clinically successful knee across all major
registries.1,2
Global commercial release for JOURNEY II UK is expected to begin
in early 2020.
References
1. Australian Orthopaedic Association National Joint Replacement
Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2019
Annual Report. Adelaide: AOA,
2019.
2. National Joint Registry for England, Wales, Northern
Ireland and the Isle of
Man. 16th Annual Report. 2019. Hertfordshire, UK.
3. Ho JC, Stitzlein RN, Green CJ, Stoner T, Froimson MI.
Return to Sports Activity following UKA and TKA. J Knee
Surg. 2016;29:254-259.
4. Witjes S, Gouttebarge V, Kuijer PP, van Geenan RC,
Poolman RW, Kerkhoffs GM. Return to Sports and Physical Activity
After Total and Unicondylar Knee Arthroplasty: A Systematic Review
and Meta-Analysis. Sports Med. 2016;46:269–292.
5. Jennings, JM, Kleeman-Forsthuber LT, Bolognesi MP.
Medial Unicompartmental Arthroplasty of the Knee. J Am Acad
Orthop Surg. 2019;27(5):166-76.
6. Griffin T, Rowden N, Morgan D, Atkinson R, Woodruff P,
Maddern G. Unicompartmental knee arthroplasty for the treatment of
unicompartmental osteoarthritis: a systematic study. ANZ J
Surg. 2007;77(4):214–221.
7. Katayama M, Higuchi H, Kimura M, et al. Proprioception
and performance after anterior cruciate ligament
rupture. International Orthopaedics.
2004:28(5):278-281.
8. Willis-Owen CA, Brust K, Alsop H, Miraldo M, Cobb JP.
Unicondylar knee arthroplasty in the UK National Health Service: An
analysis of candidacy, outcome and cost efficacy. The
Knee. 2009;16(6):473–478.
9. Fabre-Aubrespy M, Ollivier M, Pesenti S, Parratte S,
Argenson JN. Unicompartmental Knee Arthroplasty in Patients Older
Than 75 Results in Better Clinical Outcomes and Similar
Survivorship Compared to Total Knee Arthroplasty. A Matched
Controlled Study. J Arthroplasty.
2016;31(12):2668-2671.
10. Chatellard R, Sauleau V, Colmar M, Robert H, Raynaud G,
Brilhault J. Medial unicompartmental knee arthroplasty: does tibial
component position influence clinical outcomes and arthroplasty
survival? Orthop Traumatol Surg Res. 2013;99(4
Supp):S219-S225.
11. Kim MS, Koh IJ, Choi YJ, Lee JY, In Y. Differences in
Patient-Reported Outcomes Between Unicompartmental and Total Knee
Arthroplasties: A Propensity Score-Matched Analysis. J
Arthroplasty. 2017;32(5):1453-1459.
12. Zuiderbaan HA, van der List JP, Khamaisy S, et al.
Unicompartmental knee arthroplasty versus total knee arthroplasty:
Which type of artificial joint do patients forget? Knee
Surg Sports Traumatol Arthrosc. 2017;25(3):681-686.
13. McAllister CM. The Role of Unicompartmental Knee
Arthroplasty Versus Total Knee Arthroplasty in Providing Maximal
Performanceand Satisfaction. J Knee
Surg.2008;21(4):286–292.
14. Von Keudell A, Sodha S, Collins J, Minas T, Fitz W,
Gomoll AH. Patient satisfaction after primary total and
unicompartmental knee arthroplasty: An age-dependent
analysis. The Knee. 2014;21(1):180–184.
15. Data on file with Smith & Nephew. 71281465 REV0 JOURNEY
UNI Design Rationale 0710.
16. Robertsson O, Borgquist L, Knutson K, Lewold S, Lidgren
L. Use of unicompartmental instead of tricompartmental prostheses
for unicompartmental arthrosis in the knee is a cost-effective
alternative. 15,437 primary tricompartmentalprostheses were
compared with 10,624 primary medial or lateral unicompartmental
prostheses. Acta Orthop Scand. 1999;70(2):170-175.
17. Liddle AD, Pandit H, Judge A, Murray DW. Optimal usage
of unicompartmental knee arthroplasty. Bone Joint
J. 2015;97-B:1506–1511.
18. Brown NM, Sheth NP, Davis K, et al. Total Knee
Arthroplasty Has Higher Postoperative Morbidity Than
Unicompartmental Knee Arthroplasty: A Multicenter
Analysis. J Arthroplasty. 2012:27(8):86-90.
19. Bruni D, Iacono F, Akkawi I, et al. Unicompartmental Knee
Replacement: a historical overview.
JOINTS 2013;1(2):45-47.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business that exists to restore people's bodies and
their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 16,000+
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Advanced
Wound Management and Sports Medicine & ENT. Founded in
Hull, UK, in 1856, we now operate
in more than 100 countries, and generated annual sales of
$4.9 billion in 2018. Smith+Nephew is
a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group'
and 'Smith+Nephew' are used to refer to Smith & Nephew
plc and its consolidated subsidiaries, unless the context
requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: economic
and financial conditions in the markets we serve, especially those
affecting health care providers, payers and customers; price levels
for established and innovative medical devices; developments in
medical technology; regulatory approvals, reimbursement decisions
or other government actions; product defects or recalls or other
problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims;
legal compliance risks and related investigative, remedial or
enforcement actions; disruption to our supply chain or operations
or those of our suppliers; competition for qualified personnel;
strategic actions, including acquisitions and dispositions, our
success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that
affect us or our markets, including those of a political, economic,
business, competitive or reputational nature. Please refer to the
documents that Smith+Nephew has filed with the U.S. Securities and
Exchange Commission under the U.S. Securities Exchange Act of 1934,
as amended, including Smith+Nephew's most recent annual report on
Form 20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks
registered US Patent and Trademark Office.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/smithnephew-announces-first-surgeries-using-new-journey-ii-unicompartmental-knee-system-300968013.html
SOURCE Smith+Nephew